Literature DB >> 19762906

Thrombolysis targeting MRI defined tissue at risk in minor stroke.

A Kruetzelmann1, S Siemonsen, C Gerloff, M Rosenkranz, J Röther, J Fiehler, G Thomalla.   

Abstract

BACKGROUND: Treatment with intravenous tissue plasminogen activator (IV-tPA) is usually not recommended in patients with minor stroke. Clinical and imaging outcome were studied after IV-tPA treatment based on MRI criteria in patients with minor stroke.
METHODS: Data were analysed retrospectively of acute ischaemic stroke patients with minor stroke (National Institutes of Health Stroke Scale (NIHSS) score <4). All patients were studied by stroke MRI including perfusion and diffusion weighted imaging (PWI and DWI) and treated with IV-tPA for < or =6 h. Final infarct volume was delineated on follow-up MRI. Clinical outcome was assessed after 90 days using the modified Rankin Scale (mRS).
RESULTS: Six patients with a median NIHSS on admission of 2 (range 0-3) were treated with IV-tPA based on MRI criteria. In all patients, occlusion of the middle cerebral artery (MCA) was detected (MCA branch n = 2, MCA trunk n = 3, MCA trifurcation n = 1), and the PWI lesion (41, 25-60 ml) exceeded the DWI lesion (4, 1-23 ml). Final infarct volume was 9 (2-29) ml. Favourable outcome (mRS 0-1) was seen in 5/6 patients and independent outcome (mRS = 2) in one patient. No intracerebral haemorrhages occurred.
CONCLUSION: Treatment with IV-tPA based on MRI criteria was safe and appeared to be effective in this small series of patients with minor stroke.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762906     DOI: 10.1136/jnnp.2008.157313

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Critical MRI markers in transient ischemic attack.

Authors:  Thomas Ritzenthaler; Tae-Hee Cho; Guy Louis-Tisserand; Yves Berthezene; Norbert Nighoghossian
Journal:  Neurol Sci       Date:  2015-07-08       Impact factor: 3.307

2.  Screening with MRI for Accurate and Rapid Stroke Treatment: SMART.

Authors:  Shreyansh Shah; Marie Luby; Karen Poole; Teresa Morella; Elizabeth Keller; Richard T Benson; John K Lynch; Zurab Nadareishvili; Amie W Hsia
Journal:  Neurology       Date:  2015-05-13       Impact factor: 9.910

Review 3.  Intravenous thrombolysis for minor stroke and rapidly improving symptoms: a quantitative overview.

Authors:  Qiang Huang; Qingfeng Ma; Jianping Jia; Jian Wu
Journal:  Neurol Sci       Date:  2014-07-26       Impact factor: 3.307

4.  What is still missing in acute-phase treatment of stroke: a prospective observational study.

Authors:  Sara Mazzucco; Giulia Turri; Rina Mirandola; Paolo Bovi; Giulia Bisoffi
Journal:  Neurol Sci       Date:  2012-03-31       Impact factor: 3.307

5.  Intravenous tissue plasminogen activator for patients with minor ischemic stroke.

Authors:  Branko N Huisa; Rema Raman; Will Neil; Karin Ernstrom; Thomas M Hemmen
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-04-30       Impact factor: 2.136

6.  ABCD² score may discriminate minor stroke from TIA on patient admission.

Authors:  Hui Zhao; Qingjie Li; Mengru Lu; Yuan Shao; Jingwei Li; Yun Xu
Journal:  Transl Stroke Res       Date:  2013-10-17       Impact factor: 6.829

7.  Clinical and Imaging Outcomes of Endovascular Therapy in Patients with Acute Large Vessel Occlusion Stroke and Mild Clinical Symptoms.

Authors:  Meredith T Bowen; Leticia C Rebello; Mehdi Bouslama; Diogo C Haussen; Jonathan A Grossberg; Nicolas A Bianchi; Samir Belagaje; Aaron Anderson; Michael R Frankel; Raul G Nogueira
Journal:  Interv Neurol       Date:  2017-11-23

8.  Safety and outcome of thrombolysis in mild stroke: a meta-analysis.

Authors:  Lei Shi; Min Zhang; Hengfang Liu; Bo Song; Changdong Song; Dandan Song; Yuming Xu
Journal:  Med Sci Monit       Date:  2014-11-02

9.  Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke.

Authors:  Joon-Tae Kim; Man-Seok Park; Jane Chang; Ji Sung Lee; Kang-Ho Choi; Ki-Hyun Cho
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.